Gilead and Merck end EVOKE-03 Trodelvy-Keytruda lung cancer study after missing PFS endpoint; oral lenacapavir-islatravir HIV combo hits primary endpoint in two Phase 3 trials.
Partners Gilead Sciences and Merck have reported a hit and a miss for their Phase 3 HIV and lung cancer programs, respectively, but investors were …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial - Gilead Sciences (NASDAQ:GILD), Merck & Co (NYS
As Gilead's Trodelvy stumbles in first-line lung cancer, all eyes turn to Merck, AZ and Daiichi rivals
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
Merck, Gilead score in effort to develop the first weekly HIV pill
The era of the one-size-fits-all Cancer drug is ending
Sanofi stops immune drug trial in latest research setback
Gilead and Merck's latest trial success and flop
Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet…
Gilead And Merck Report Phase 3 HIV Trial Success As Separate Lung Cancer Study Of Trodelvy-Keytruda Combination Ends
Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to…
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral…
Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout
